Veledimex

Veledimex (INXN-1001), a synthetic analog of the insect molting hormone ecdysone, is an orally active activator ligand for a proprietary gene therapy promoter system. Veledimex can be used to activate certain genes using the ecdysone receptor (EcR) -based inducible gene regulation system, the RheoSwitch Therapeutic System (RTS) . Veledimex can cross blood-brain barrier (BBB) in both orthotopic GL-261 mice and cynomolgus monkeys[1][2].

Product Specifications

CAS Number

[1093130-72-3]

Product Name Alternative

INXN-1001; RG-115932

UNSPSC

12352005

Target

Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Veledimex.html

Purity

98.77

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(NN(C(C1=CC(C)=CC(C)=C1)=O)[C@@H](C(C)(C)C)CCC)C2=CC=CC(OC)=C2CC

Molecular Formula

C27H38N2O3

Molecular Weight

438.60

References & Citations

[1]Barrett JA, et al. Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma. Cancer Gene Ther. 2018;25 (5-6) :106-116.|[2]Chiocca EA, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 2019;11 (505) :eaaw5680.